{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T23:56:12Z","timestamp":1788738972198,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020192","name":"Medtronic Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020192","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Microwave ablation (MWA) is a treatment modality for colorectal liver metastases (CRLM). While potentially curative, more information is needed on factors that contribute to long-term local tumour control. The prospective multicentre observational study CIRSE Emprint Microwave Ablation Registry aims to prospectively collect real-world technical data and clinical outcomes on patients treated with MWA in CRLM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Eligible patients are adults with up to 9 local treatment na\u00efve CRLM of\u2009\u2264\u20093\u00a0cm completely treatable with either MWA alone or MWA with resection and\/or radiotherapy within 8\u00a0weeks. Data are collected, at baseline, every 3\u00a0months until 12\u00a0months, and thereafter every 6\u00a0months until the end of the study. The primary outcome measure is local tumour control. Secondary outcome measures are overall survival, (hepatic-) disease-free survival, time-to-progression untreatable by ablation, systemic therapy vacation, safety, and quality of life. Covariates related to the primary outcome measure will be assessed using a stratified log-rank test and an univariable Cox proportional hazard regression. A sample size of 500 patients with 750 lesions produces a two-sided 95% confidence interval with a precision equal to 0.057.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between September 2019 and December 2022, 500 patients have been enrolled with at least 976 treated tumours.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The prospective observational CIEMAR study will provide valuable insights into the real-world use of MWA, helping in the future patient selection and clarifying factors that may contribute to long-term local tumour control.<\/jats:p>\n                <jats:p><jats:italic>Trial Registration<\/jats:italic>: NCT03775980.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00270-023-03573-0","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T17:02:09Z","timestamp":1698339729000},"page":"121-129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Local Tumour Control Following Microwave Ablation: Protocol for the Prospective Observational CIEMAR Study"],"prefix":"10.1007","volume":"47","author":[{"given":"Philippe L.","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto","family":"Bale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5smund Avdem","family":"Fretland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Nahum","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Helmberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn R.","family":"Meijerink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Orsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"St\u00e4ttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kafkoula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2377-2973","authenticated-orcid":false,"given":"Niels","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bleranda","family":"Zeka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"de Ba\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"issue":"3","key":"3573_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329\u201359.","journal-title":"J Natl Compr Canc Netw."},{"issue":"1","key":"3573_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2022","unstructured":"Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;34(1):10\u201332.","journal-title":"Ann Oncol."},{"issue":"6","key":"3573_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/00000658-200206000-00002","volume":"235","author":"MA Choti","year":"2002","unstructured":"Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759\u201366.","journal-title":"Ann Surg"},{"issue":"5","key":"3573_CR4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/01.sla.0000160703.75808.7d","volume":"241","author":"TM Pawlik","year":"2005","unstructured":"Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241(5):715\u201322.","journal-title":"Ann Surg."},{"key":"3573_CR5","first-page":"283","volume":"4","author":"GP Kanas","year":"2012","unstructured":"Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283\u2013301.","journal-title":"Clin Epidemiol"},{"issue":"2","key":"3573_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jvir.2017.08.021","volume":"29","author":"W Shady","year":"2018","unstructured":"Shady W, Petre EN, Do KG, Gonen M, Yarmohammadi H, Brown KT, et al. Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: ablation with clear margins (A0) provides the best local tumor control. J Vasc Interv Radiol. 2018;29(2):268\u201375.","journal-title":"J Vasc Interv Radiol."},{"issue":"3","key":"3573_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1200\/JCO.2009.23.4450","volume":"28","author":"SL Wong","year":"2010","unstructured":"Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD 3rd, Dorfman GS, et al. american society of clinical oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010;28(3):493\u2013508.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3573_CR8","doi-asserted-by":"publisher","first-page":"dxj015","DOI":"10.1093\/jnci\/djx015","volume":"109","author":"T Ruers","year":"2017","unstructured":"Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017;109(9):dxj015.","journal-title":"J Natl Cancer Inst."},{"issue":"10","key":"3573_CR9","doi-asserted-by":"publisher","first-page":"e990","DOI":"10.1634\/theoncologist.2018-0337","volume":"24","author":"F Izzo","year":"2019","unstructured":"Izzo F, Granata V, Grassi R, Fusco R, Palaia R, Delrio P, et al. Radiofrequency ablation and microwave ablation in liver tumors: an update. Oncologist. 2019;24(10):e990\u20131005.","journal-title":"Oncologist"},{"issue":"5","key":"3573_CR10","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.ejso.2019.12.003","volume":"46","author":"M Di Martino","year":"2020","unstructured":"Di Martino M, Rompianesi G, Mora-Guzman I, Martin-Perez E, Montalti R, Troisi RI. Systematic review and meta-analysis of local ablative therapies for resectable colorectal liver metastases. Eur J Surg Oncol. 2020;46(5):772\u201381.","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"3573_CR11","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1111\/j.1463-1318.2011.02695.x","volume":"13","author":"S Pathak","year":"2011","unstructured":"Pathak S, Jones R, Tang JM, Parmar C, Fenwick S, Malik H, et al. Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Dis. 2011;13(9):e252\u201365.","journal-title":"Colorectal Dis"},{"issue":"1","key":"3573_CR12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41598-021-03802-x","volume":"12","author":"A Radosevic","year":"2022","unstructured":"Radosevic A, Quesada R, Serlavos C, Sanchez J, Zugazaga A, Sierra A, et al. Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial. Sci Rep. 2022;12(1):316.","journal-title":"Sci Rep"},{"issue":"7","key":"3573_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11547-014-0415-y","volume":"119","author":"TJ Vogl","year":"2014","unstructured":"Vogl TJ, Farshid P, Naguib NN, Darvishi A, Bazrafshan B, Mbalisike E, et al. Thermal ablation of liver metastases from colorectal cancer: radiofrequency, microwave and laser ablation therapies. Radiol Med. 2014;119(7):451\u201361.","journal-title":"Radiol Med"},{"issue":"11","key":"3573_CR14","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1055\/s-0043-117410","volume":"189","author":"TJ Vogl","year":"2017","unstructured":"Vogl TJ, Nour-Eldin NA, Hammerstingl RM, Panahi B, Naguib NNN. Microwave ablation (MWA): basics, technique and results in primary and metastatic liver neoplasms\u2014review article. Rofo. 2017;189(11):1055\u201366.","journal-title":"Rofo"},{"issue":"3","key":"3573_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1067\/j.cpradiol.2007.10.001","volume":"38","author":"CL Brace","year":"2009","unstructured":"Brace CL. Radiofrequency and microwave ablation of the liver, lung, kidney, and bone: what are the differences? Curr Probl Diagn Radiol. 2009;38(3):135\u201343.","journal-title":"Curr Probl Diagn Radiol"},{"issue":"8","key":"3573_CR16","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s00270-022-03152-9","volume":"45","author":"RS Puijk","year":"2022","unstructured":"Puijk RS, Dijkstra M, van den Bemd BAT, Ruarus AH, Nieuwenhuizen S, Geboers B, et al. Improved outcomes of thermal ablation for colorectal liver metastases: a 10-year analysis from the prospective Amsterdam CORE registry (AmCORE). Cardiovasc Intervent Radiol. 2022;45(8):1074\u201389.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"3573_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1186\/s12885-018-4716-8","volume":"18","author":"RS Puijk","year":"2018","unstructured":"Puijk RS, Ruarus AH, Vroomen L, van Tilborg A, Scheffer HJ, Nielsen K, et al. Colorectal liver metastases: surgery versus thermal ablation (COLLISION)\u2014a phase III single-blind prospective randomized controlled trial. BMC Cancer. 2018;18(1):821.","journal-title":"BMC Cancer"},{"issue":"5","key":"3573_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"3","key":"3573_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","volume":"230","author":"Y Fong","year":"1999","unstructured":"Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309\u201318.","journal-title":"Ann Surg."},{"key":"3573_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/0471445428","volume-title":"Statistical methods for rates and proportions","author":"JL Fleiss","year":"2003","unstructured":"Fleiss JL, Levin BA, Paik MC. Statistical methods for rates and proportions. 3rd ed. New York: Wiley; 2003.","edition":"3"},{"issue":"8","key":"3573_CR21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","volume":"17","author":"RG Newcombe","year":"1998","unstructured":"Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857\u201372.","journal-title":"Stat Med"},{"issue":"25","key":"3573_CR22","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJM200006223422506","volume":"342","author":"K Benson","year":"2000","unstructured":"Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878\u201386.","journal-title":"N Engl J Med"},{"issue":"25","key":"3573_CR23","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","volume":"342","author":"J Concato","year":"2000","unstructured":"Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887\u201392.","journal-title":"N Engl J Med"},{"issue":"7","key":"3573_CR24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/jama.286.7.821","volume":"286","author":"JP Ioannidis","year":"2001","unstructured":"Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, Tektonidou MG, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA. 2001;286(7):821\u201330.","journal-title":"JAMA"},{"issue":"6","key":"3573_CR25","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/cea.14311","volume":"53","author":"D Di Bona","year":"2023","unstructured":"Di Bona D, Carlucci P, Spataro F, Paoletti G, Heffler E, Pulkanen J, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies on allergen immunotherapy. Clin Exp Allergy. 2023;53(6):610\u201325.","journal-title":"Clin Exp Allergy"},{"issue":"11","key":"3573_CR26","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/j.jvir.2014.09.005","volume":"25","author":"M Ahmed","year":"2014","unstructured":"Ahmed M. Technology assessment committee of the society of interventional R. image-guided tumor ablation: standardization of terminology and reporting criteria\u2013a 10-year update: supplement to the consensus document. J Vasc Interv Radiol. 2014;25(11):1706\u20138.","journal-title":"J Vasc Interv Radiol."},{"issue":"2","key":"3573_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrclinonc.2014.199","volume":"12","author":"JM Franklin","year":"2015","unstructured":"Franklin JM, Gebski V, Poston GJ, Sharma RA. Clinical trials of interventional oncology-moving from efficacy to outcomes. Nat Rev Clin Oncol. 2015;12(2):93\u2013104.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"3573_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1056\/NEJMra1614394","volume":"377","author":"TR Frieden","year":"2017","unstructured":"Frieden TR. Evidence for health decision making\u2014beyond randomized. Controll Trials N Engl J Med. 2017;377(5):465\u201375.","journal-title":"Controll Trials N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s00270-023-03618-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000}}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-023-03573-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-023-03573-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-023-03573-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T15:02:33Z","timestamp":1704466953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-023-03573-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["3573"],"URL":"https:\/\/doi.org\/10.1007\/s00270-023-03573-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00270-023-03618-4","asserted-by":"object"}]},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"28 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00270-023-03618-4","URL":"https:\/\/doi.org\/10.1007\/s00270-023-03618-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Philippe L. Pereira reported being on advisory boards, receiving honoraria and speaker fees from Medtronic, Angiodynamics, and Boston Scientific. \u00c5smund Avdem Fretland has received a speaker honorarium from Bayer and Olympus. S. Nahum Goldberg has received consulting fees from Cambridge Interventional, CAPS Medical, and XACT Robotics, support for attending meetings and\/or travel from Cambridge Interventional, and institutional support for a clinical study from XACT Robotics. Thomas Helmberger received speaker honoraria from SIRTEX Medical Europe. Martijn R. Meijerink, Reto Bale, Thomas Vogl, Franco Orsi, Stefan St\u00e4ttner, Thierry de Baere, Anna Kafkoula, Bleranda Zeka, and Niels de Jong reported no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"For this type of study, consent for publication is not required. However, consent for publication was obtained for every individual person\u2019s data included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}]}}